Return
Golimumab
DOI:10.1038/nrd2982.png)
Abstract
En
Keywords:
ACTIVE RHEUMATOID-ARTHRITIS
NECROSIS-FACTOR-ALPHA
DOUBLE-BLIND
PLUS METHOTREXATE
MONOCLONAL-ANTIBODY
PHASE-III
THERAPY
SAFETY
TRIAL
MULTICENTER
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
101.8
Papers:
5.1K
Citations:
5.3W
Organization
Cited Papers
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
LANCET
IF88.5

